Evidence map›Paper›PMID 11092283›Full record

Trial reportDiabetes care2000

The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.

2 registry-linked trialsAbstract readClinical TrialMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 165 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04855552 naactive not recruitingnot on this mapstarted 2021, after this paper: background citation

Pilot Telehealth Weight Loss Program for Breast Cancer Survivors

TypeinterventionalSponsorAbramson Cancer Center at Penn MedicineRan2021 to 2027Enrolled22ConditionsCancer Survivors, Cancer of Breast, Body Weight, Overweight and ObesityArmsBehavioral Weight-loss Program Via Telehealth, Behavioral Weight-Loss Program Via Telehealth - Weight Measures, Validated Surveys of Patient-Reported Outcomes
NCT06067139 narecruitingnot on this mapstarted 2023, after this paper: background citation

Sleep for Health: A Randomized Clinical Trial Examining the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk

TypeinterventionalSponsorKaiser PermanenteRan2023 to 2027Enrolled300ConditionsDiabetes Mellitus, Type 2, Prediabetic State, Sleep Initiation and Maintenance DisordersArmsSHUTi, Patient Education
3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Interventions to improve adherence to lipid-lowering medication.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Interventions to improve adherence to lipid lowering medication.The Cochrane database of systematic reviews · 2004
    Pooled it
  10. Trial
  11. Trial
  12. Prediabetes Subgroups, Type 2 Diabetes Risk, and Differential Effects of Preventive Interventions.The Journal of clinical endocrinology and metabolism · 2025 · on this map
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Trial
  18. Trial
  19. Trial
  20. Trial

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

0 authors.

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
NIDDK NIH HHS U01 DK048489
6 · The paper itself

Abstract

objectiveThe Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes. RESEARCH DESIGN AND

methodsEligibility requirements were age > or = 25 years, BMI > or = 24 kg/m2 (> or = 22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or < or = 6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups--intensive lifestyle modification, standard care plus metformin, and standard care plus placebo--are presented for the 3,234 participants who have been randomized.

resultsOf all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 +/- 10.7 years (mean +/- SD), and 67.7% were women. Moreover, 16% were < 40 years of age, and 20% were > or = 60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 +/- 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI > or = 30 kg/m2. Average fasting plasma glucose (6.0 +/- 0.5 mmol/l) and HbA1c (5.9 +/- 0.5%) in men were comparable with values in women (5.9 +/- 0.4 mmol/l and 5.9 +/- 0.5%, respectively).

conclusionsThe DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.

Indexed as

Patient Education as TopicAdultAsianBlack or African AmericanBlood GlucoseBlood PressureBody Mass IndexCholesterolCohort StudiesCoronary DiseaseDiabetes Mellitus, Type 2FemaleGlucose IntoleranceHispanic or LatinoHumansHypercholesterolemiaBlood GlucoseCholesterolLipids

Identifiers

PMID11092283
PMCPMC1360735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.